Bosses want you to know AI is coming for your job
SAN FRANCISCO - Top executives at some of the largest American companies have a warning for their workers: Artificial intelligence is a threat to your job.
CEOs from Amazon to IBM, Salesforce and JPMorgan Chase are telling their employees to prepare for disruption as AI either transforms or eliminates their jobs in the future.
Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post.
AI will 'improve inventory placement, demand forecasting and the efficiency of our robots,' Amazon CEO Andy Jassy said in a Tuesday public memo that predicted his company's corporate workforce will shrink 'in the next few years.' He joins a string of other top executives that have recently sounded the alarm about AI's impact in the workplace.
Economists say there aren't yet strong signs that AI is driving widespread layoffs across industries. But there is evidence that workers across the United States are increasingly using AI in their jobs and the technology is starting to transform some roles such as computer programming, marketing and customer service. At the same time, CEOs are under pressure to show they are embracing new technology and getting results - incentivizing attention-grabbing predictions that can create additional uncertainty for workers.
'It's a message to shareholders and board members as much as it is to employees,' Molly Kinder, a Brookings Institution fellow who studies the impact of AI, said of the CEO announcements, noting that when one company makes a bold AI statement, others typically follow. 'You're projecting that you're out in the future, that you're embracing and adopting this so much that the footprint [of your company] will look different.'
Some CEOs fear they could be ousted from their job within two years if they don't deliver measurable AI-driven business gains, a Harris Poll survey conducted for software company Dataiku showed.
Tech leaders have sounded some of the loudest warnings - in line with their interest in promoting AI's power. At the same time, the industry has been shedding workers the last few years after big hiring sprees during the height of the coronavirus pandemic and interest rate hikes by the Federal Reserve.
At Amazon, Jassy told the company's workers that AI would in 'the next few years' reduce some corporate roles like customer service representatives and software developers, but also change work for those in the company's warehouses.
IBM, which recently announced job cuts, said it replaced a couple hundred human resource workers with AI 'agents' for repetitive tasks such as onboarding and scheduling interviews. In January, Meta CEO Mark Zuckerberg suggested on Joe Rogan's podcast that the company is building AI that might be able to do what some human workers do by the end of the year.
'We, at Meta as well as the other companies working on this, are going to have an AI that can effectively be sort of a mid-level engineer at your company,' Zuckerberg said. 'Over time we'll get to the point where a lot of the code in our apps … is actually going to be built by AI engineers instead of people engineers.'
Dario Amodei, CEO of Anthropic, maker of the chatbot Claude, boldly predicted last month that half of all white-collar entry-level jobs may be eliminated by AI within five years.
Leaders in other sectors have also chimed in. Marianne Lake, JPMorgan's CEO of consumer and community banking, told an investor meeting last month that AI could help the bank cut headcount in operations and account services by 10 percent. The CEO of BT Group Allison Kirkby suggested that advances in AI would mean deeper cuts at the British telecom company.
Even CEOs who reject the idea of AI replacing humans on a massive scale are warning workers to prepare for disruption. Jensen Huang, CEO of AI chip designer Nvidia said last month, 'You're not going to lose your job to an AI, but you're going to lose your job to someone who uses AI.'
Google CEO Sundar Pichai said at Bloomberg's tech conference this month that AI will help engineers be more productive but that his company would still add more human engineers to its team. Meanwhile, Microsoft is planning more layoffs amid heavy investment in AI, Bloomberg reported this week. Other tech leaders at Shopify, Duolingo and Box have told workers they are now required to use AI at their jobs, and some will monitor usage as part of performance reviews.
Some companies have indicated that AI could slow hiring. Salesforce CEO Marc Benioff recently called Amodei's prognosis 'alarmist' on an earnings call, but on the same call chief operating and financial officer Robin Washington said that an AI agent has helped to reduce hiring needs and bring $50 million in savings.
Despite corporate leaders' warnings, economists don't yet see broad signs that AI is driving humans out of work. 'We have little evidence of layoffs so far,' said Columbia Business School professor Laura Veldkamp, whose research explores how companies' use of AI affects the economy. 'What I'd look for are new entrants with an AI-intensive business model, entering and putting the existing firms out of business.'
Some researchers suggest there is evidence AI is playing a role in the drop in openings for some specific jobs, like computer programming, where AI tools that generate code have become standard. Google's Pichai said last year that more than a quarter of new code at the company was initially suggested by AI.
Many other workers are increasingly turning to AI tools, for everything from creating marketing campaigns to helping with research - with or without company guidance. The percentage of American employees who use AI daily has doubled in the last year to 8 percent, according to a Gallup poll released this week. Those using it at least a few times a week jumped from 12 percent to 19 percent.
Some AI researchers say the poll may not actually reflect the total number of workers using AI as many may use it without disclosing it.
'I would suspect the numbers are actually higher,' said Ethan Mollick, co-director of Wharton School of Business' generative AI Labs, because some workers avoid disclosing AI usage, worried they would be seen as less capable or breaching corporate policy. Only 30 percent of respondents to the Gallup survey said that their company had general guidelines or formal policies for using AI.
OpenAI's ChatGPT, one of the most popular chatbots, has more than 500 million weekly users around the globe, the company has said.
It is still unclear what benefits companies are reaping from employees' use of AI, said Arvind Karunakaran, a faculty member of Stanford University's Center for Work, Technology, and Organization.
'Usage does not necessarily translate into value,' he said. 'Is it just increasing productivity in terms of people doing the same task quicker or are people now doing more high value tasks as a result?'
Lynda Gratton, a professor at London Business School, said predictions of huge productivity gains from AI remain unproven.
'Right now, the technology companies are predicting there will be a 30% productivity gain. We haven't yet experienced that, and it's not clear if that gain would come from cost reduction … or because humans are more productive.'
The pace of AI adoption is expected to accelerate even further if more companies use advanced tools such as AI agents and they deliver on their promise of automating work, Mollick said. AI labs are hoping to prove their agents are reliable within the next year or so, which will be a bigger disrupter to jobs, he said.
While the debate continues over whether AI will eliminate or create jobs, Mollick said 'the truth is probably somewhere in between.'
'A wave of disruption is going to happen,' he said.
Related Content
3-pound puppy left in trash is rescued, now thriving
How to meet street cats around the world
'Jaws' made people fear sharks. 50 years later, can it help save them?

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
41 minutes ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on


Forbes
42 minutes ago
- Forbes
Google's Quiet Confirmation Of The Pixel 10
Google's "Talking Phones Podcast" title card Google is having a little bit of fun in its latest iPhone vs Pixel video. While the Pixel 9 Pro takes pride of place, there's also a surprising cameo for what comes next… the Pixel 10. The Pixel 10 Easter Egg The details come at the end of Google's latest promotional video posted on its Made By Google YouTube channel. In it, an iPhone and a Pixel talk about the recent advances made by Apple's smartphone, with a not at all surprised Pixel noting when that feature arrived on Pixel and Android. These include live translation, hold assistance and call screening arriving four, five and seven years ago respectively., Of course, the capabilities of all these features have improved significantly over the last few years, so there are shades of Oranges to (ahem) Apples here, but it makes Google's point effectively. The story of Android being ahead of iOS is here for all to hear. The little easter egg at the end is part of another story, leading into the next Pixel release. The iPhone quietly asks the Pixel 9 Pro, 'so, what are you working on for Pixel 10… just out of curiosity?' Naming The Pixel 10 It's no secret that Google is working on the next family of Pixel smartphones. Neither is it a secret that we're expecting an entry-level Pixel 10, a premium Pixel 10 Pro, a larger Pixel 10 Pro XL and an innovative Pixel 10 Pro Fold. Yet this is the first time Google has publicly acknowledged that the new handsets will carry the Pixel 10 branding. Although the sharp-eared watchers will note that it was the iPhone confirming the new Pixel 10, not the Pixel 9 Pro. So, did Apple confirm the new name, rather than Google? Google is expected to announce the Pixel 10 family at an upcoming Made By Google event. While dates have not been confirmed, talk within the community picks out Wednesday, Aug. 20 for the launch, and Thursday, Aug 28. for the first handsets to go on sale to the public. Now read how the Pixel 10 will impact every Android smartphone in 2025 and beyond…